Neuronetics Inc. (NASDAQ: STIM) announced the appointment of Dan Reuvers as president and chief executive officer, effective March 23, 2026. Reuvers will also join the board of directors at that time.

Reuvers succeeds Keith Sullivan, who will step down as president and CEO on March 23, 2026 and retire on March 31, 2026 after leading the company for five and a half years.

Reuvers most recently served as president and CEO of Tactile Medical (NASDAQ: TCMD), where he grew revenue from $187 million to approximately $300 million. Prior to Tactile Medical, he spent 12 years at Integra LifeSciences (NASDAQ: IART), rising to executive vice president and president of Codman Specialty Surgical, a $1 billion global neurosurgery division.

"Dan is a proven public company CEO with more than three decades of experience building and scaling medical technology businesses," said Rob Cascella, Neuronetics' chairman of the board.

In connection with his employment, Reuvers received an inducement grant of 1.5 million restricted stock units that vest in equal installments on the first, second, and third anniversary of his start date, subject to continued employment. The grant was approved by the company's board of directors as recommended by the compensation committee.

Neuronetics develops medical technology products for neurohealth disorders and operates treatment centers across the United States through its Greenbrook TMS subsidiary. The company's NeuroStar Advanced Therapy System is cleared by the FDA for treating major depressive disorder in adults and adolescents aged 15-21, among other indications.